In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Open Access
Abstract
Over 36 million people worldwide are infected with HIV. Antiretroviral therapy (ART) has proven to be highly effective to prevent HIV-1 transmission, clinical progression and death. Despite this success, the number of HIV-1 infected individuals continues increasing and ART should be taken for life. Therefore, there are two main priorities: the development of preventive vaccines to protect from HIV acquisition and achieve an efficient control of HIV infection in the absence of ART (functional cure). In this sense, in the last few years, there has been a broad interest in new and innovative approaches such as mRNA-based vaccines. RNA-based immunogens represent a promising alternative to conventional vaccines because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. Some mRNA-based vaccines platforms against infectious diseases have demonstrated encouraging results in animal models and humans. However, their application is still limited because the instability and inefficient in vivo delivery of mRNA. Immunogens, design, immunogenicity, chemical modifications on the molecule or the vaccine delivery methods are all crucial interventions for improvement. In this review we, will present the current knowledge and challenges in this research field. mRNA vaccines hold great promises as part of a combined strategy, for achieving HIV functional cure.Keywords
Funding Information
- European Commission (FP7-HEALTH-2013-INNOVATION-1 602570-2 and H2020-SC1-2016-2017)
- Spanish Ministry of Economy (MINECO) (SAF2015-66193-R and RTI2018-096309-B-I00)
- Instituto de Salud Carlos III (COV20/00214 and ICI20/00067)
- CERCA Programme / Generalitat de Catalunya (SGR 615 and SGR 653)
- Fondo de Investigación Sanitaria (FIS) (AC16/00051 and PI18/00699)
This publication has 100 references indexed in Scilit:
- RNA: The new revolution in nucleic acid vaccinesSeminars in Immunology, 2013
- Nonviral delivery of self-amplifying RNA vaccinesProceedings of the National Academy of Sciences of the United States of America, 2012
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie International Edition, 2012
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patientsJournal of Clinical Investigation, 2011
- Natural and engineered nicking endonucleases--from cleavage mechanism to engineering of strand-specificityNucleic Acids Research, 2010
- Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapyClinical Immunology, 2010
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- High Guanine and Cytosine Content Increases mRNA Levels in Mammalian CellsPLOS Biology, 2006
- Cellular Immune Responses in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Effects of Vaccination with Recombinant Envelope Glycoprotein ofHIV-1Clinical and Vaccine Immunology, 2006